PMID- 36090550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220913
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 10
DP  - 2022
TI  - Protective effect of inhaled corticosteroid on children with asthma with 
      Mycoplasma pneumoniae pneumonia.
PG  - 908857
LID - 10.3389/fped.2022.908857 [doi]
LID - 908857
AB  - BACKGROUND: The aim of this study was to determine the differences in the 
      characteristics of Mycoplasma pneumoniae pneumonia (MPP) in children with and 
      without asthma and in children with asthma with and without inhaled 
      corticosteroid (ICS) therapy in order to determine the risk factors for asthma 
      exacerbation and the effect of regular ICS therapy on children with asthma with 
      MPP. MATERIALS AND METHODS: Children with MPP were divided into two groups 
      according to whether they had a history of asthma. Children with asthma were 
      further divided into an ICS therapy group and a group without ICS therapy. The 
      clinical characteristics, laboratory test results, and pulmonary images were 
      compared between the children with and without asthma. Differences in the 
      severity of acute exacerbation were compared between the children with asthma in 
      the ICS therapy and without ICS therapy groups. Multivariable logistic regression 
      was used to determine the risk factors for exacerbation of MPP in children with 
      asthma. RESULTS: In children with MPP, the differences in the eosinophil counts; 
      total immunoglobulin E (IgE), C-reactive protein, procalcitonin (PCT), and 
      lactate dehydrogenase (LDH) levels; and fever duration, wheezing, extrapulmonary 
      complications, oxygen saturation < 92%, severe pneumonia, pleural effusion, 
      co-infection with other pathogens, and lobar pneumonia between children with and 
      without asthma were statistically significant. Among children with asthma with 
      MPP, those in the ICS therapy group were less likely to experience an 
      exacerbation, and exacerbations were less severe than those in the without ICS 
      therapy group. The multivariable logistic regression analysis showed that the ICS 
      therapy was an independent protective factor against exacerbation. CONCLUSION: 
      Among children with MPP, the chance of wheezing was higher in children with 
      asthma than in children without asthma. The ICS therapy was a protective factor 
      against exacerbation in children with asthma with MPP.
CI  - Copyright (c) 2022 Wei, Dang, Liu and Li.
FAU - Wei, Bing
AU  - Wei B
AD  - Department of Neonatology, General Hospital of Northern Theater Command, 
      Shenyang, China.
FAU - Dang, Yan-Hong
AU  - Dang YH
AD  - Department of Pediatrics, Shengjing Hospital of China Medical University, 
      Shenyang, China.
FAU - Liu, Xiang-Ping
AU  - Liu XP
AD  - Department of Pediatrics, Shengjing Hospital of China Medical University, 
      Shenyang, China.
FAU - Li, Miao
AU  - Li M
AD  - Department of Pediatrics, Shengjing Hospital of China Medical University, 
      Shenyang, China.
LA  - eng
PT  - Journal Article
DEP - 20220825
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC9452955
OTO - NOTNLM
OT  - Mycoplasma pneumoniae pneumonia
OT  - asthma
OT  - children
OT  - exacerbation
OT  - inhaled corticosteroids
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:01
PMCR- 2022/08/25
CRDT- 2022/09/12 03:45
PHST- 2022/03/31 00:00 [received]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/09/12 03:45 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:01 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 10.3389/fped.2022.908857 [doi]
PST - epublish
SO  - Front Pediatr. 2022 Aug 25;10:908857. doi: 10.3389/fped.2022.908857. eCollection 
      2022.